These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19702732)

  • 21. Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis.
    Rosati A; Ilvento L; Lucenteforte E; Pugi A; Crescioli G; McGreevy KS; Virgili G; Mugelli A; De Masi S; Guerrini R
    Epilepsia; 2018 Feb; 59(2):297-314. PubMed ID: 29270989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy.
    Russo E; Citraro R; Scicchitano F; De Fazio S; Di Paola ED; Constanti A; De Sarro G
    Epilepsia; 2010 Aug; 51(8):1560-9. PubMed ID: 19919665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Juvenile absence epilepsy exacerbated by valproic acid.
    Buechler RD; Buchhalter JR
    Pediatr Neurol; 2007 Feb; 36(2):121-4. PubMed ID: 17275666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability.
    Alvarez N; Besag F; Iivanainen M
    J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():1-15. PubMed ID: 10030426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy?
    Schmitt B; Kovacevic-Preradovic T; Critelli H; Molinari L
    Neuropediatrics; 2007 Apr; 38(2):83-7. PubMed ID: 17712736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy.
    Fakhoury TA; Hammer AE; Vuong A; Messenheimer JA
    Epilepsy Behav; 2004 Aug; 5(4):532-8. PubMed ID: 15256191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection of drugs for the treatment of epilepsy.
    Mattson RH
    Semin Neurol; 1990 Dec; 10(4):406-13. PubMed ID: 2287835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Childhood and juvenile absence epilepsy. Treatment and prognosis].
    Pedersen AM; Rasmussen NH
    Ugeskr Laeger; 2004 Nov; 166(46):4133-5. PubMed ID: 15565844
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative profiles of sodium valproate and ethosuximide on electro-behavioural correlates in gamma-hydroxybutyrate and pentylenetetrazol induced absence seizures in rats.
    Kumaresan S; David J; Joseph T
    Indian J Physiol Pharmacol; 2000 Oct; 44(4):411-8. PubMed ID: 11214495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Practical Guide to Treatment of Childhood Absence Epilepsy.
    Kessler SK; McGinnis E
    Paediatr Drugs; 2019 Feb; 21(1):15-24. PubMed ID: 30734897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
    Russo E; Citraro R; Scicchitano F; De Fazio S; Perrotta I; Di Paola ED; Constanti A; De Sarro G
    Epilepsia; 2011 Jul; 52(7):1341-50. PubMed ID: 21635238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
    Montouris G; Abou-Khalil B
    Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment behavior and subsequent medication effects in childhood absence epilepsy.
    Shinnar RC; Shinnar S; Cnaan A; Clark P; Dlugos D; Hirtz DG; Hu F; Liu C; Masur D; Weiss EF; Glauser TA;
    Neurology; 2017 Oct; 89(16):1698-1706. PubMed ID: 28916534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lamotrigine therapy of epilepsy with Angelman's syndrome.
    Dion MH; Novotny EJ; Carmant L; Cossette P; Nguyen DK
    Epilepsia; 2007 Mar; 48(3):593-6. PubMed ID: 17326790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lamotrigine and absence seizures: new indication. Try valproic acid first.
    Prescrire Int; 2009 Dec; 18(104):249. PubMed ID: 20025089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethosuximide and valproate display high efficacy against lindane-induced seizures in mice.
    Kaminski RM; Tochman AM; Dekundy A; Turski WA; Czuczwar SJ
    Toxicol Lett; 2004 Dec; 154(1-2):55-60. PubMed ID: 15475178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study.
    Gericke CA; Picard F; de Saint-Martin A; Strumia S; Marescaux C; Hirsch E
    Epileptic Disord; 1999 Sep; 1(3):159-65. PubMed ID: 10937148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
    Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
    Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ezogabine treatment of childhood absence epilepsy.
    Vossler DG; Yilmaz U
    Epileptic Disord; 2014 Mar; 16(1):121-4. PubMed ID: 24659629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational polytherapy.
    French JA; Faught E
    Epilepsia; 2009 Sep; 50 Suppl 8():63-8. PubMed ID: 19702736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.